Hepatitis C--an update

Aust Fam Physician. 2013 Jul;42(7):452-6.

Abstract

Background: Chronic hepatitis C (CHC) infection remains a significant health issue. Most patients are asymptomatic, but long term infection may cause liver failure, liver cancer, and death. Projections estimate that these complications will triple by 2020. Chronic hepatitis C infection is curable, and successful viral eradication reduces liver related complications. The landscape of CHC therapy is rapidly changing.

Objective: This article outlines the incidence, prevalence and natural history of CHC, and provides information that may assist the general practitioner in the assessment and management of CHC patients.

Discussion: Chronic hepatitis C infection is under-diagnosed and may lead to significant morbidity and mortality. Currently, only 1.3% of cases are being treated. The GP plays an important role in diagnosing CHC, and provides a unique opportunity to screen patients with risk factors and refer for treatment. The first direct-acting antivirals have recently been approved, and combination all-oral therapy (interferon free) is expected in 3-5 years. Hence, all patients with CHC should be referred for treatment consideration.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Australia / epidemiology
  • Drug Therapy, Combination
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / epidemiology*
  • Humans
  • Incidence
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Male
  • Middle Aged
  • Oligopeptides / therapeutic use
  • Polyethylene Glycols / therapeutic use
  • Prevalence
  • RNA, Viral / blood
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use
  • Viral Load

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Oligopeptides
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
  • peginterferon alfa-2b